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Articular cartilage is a smooth, white connective tissue that covers and protects 
the ends of long bones to allow for a smooth, frictionless surface on which to glide for 
easy movement. Once the tissue is damaged, articular cartilage lacks a direct blood 
supply, which results in a limited ability to repair itself. This study explores the effect of 
the growth factor BMP-13 on the chondroinduction of primary human bone marrow-
derived mesenchymal stem cells.
The results demonstrate the limited ability of BMP-13 to exert a strong
chondroinductive effect on human bone marrow-derived MSCs. However, the results do
indicate that BMP-13 has the ability to sustain chondroinduction to a certain extent for up 
to 18 days following initiation by 3 days of exposure to TGF-β3. Results are encouraging
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Joint and articular cartilage injuries account for over 6 million hospital visits in 
the United States each year [1]. Wear and tear on articular cartilage can lead to a loss in 
the tissue, further exposing the ends of long bones and leaving them without protection. 
Further tissue degradation leads to the most common type of arthritis, osteoarthritis. 
Osteoarthritis, or degenerative joint disease, affects an estimated 27 million adults in the
United States [2]. 
Unlike other tissues, articular cartilage has a low regenerative capacity and once
injured finds it much more difficult to self-repair. The composition and structure of
articular cartilage give rise to the tissue’s unique properties. Due to the complexity of
articular cartilage composition, it has become challenging to restore full function to 
damaged or diseased tissue. Currently, there are many different methods employed for
treating articular cartilage lesions; however, many shortcomings exist with these
therapies.
Tissue engineering may provide alternative solutions for articular cartilage repair 
and regeneration by developing tissue substitutes that mimic the composition of articular 
cartilage. The objective of this research is to determine the precise nature and magnitude
1
  





















of growth factors that regulate chondrogenic mesenchymal stem cell (MSC)
differentiation. In order to make progress towards introducing a tissue-engineered 
technique, a basic understanding of articular cartilage structure, composition and function 
must first be established.
Articular Cartilage
Articular cartilage is a smooth, white connective tissue that covers and protects 
the ends of long bones to allow for a smooth, frictionless surface on which to glide for 
easy movement. Serving as shock absorber, articular cartilage assists in distributing the 
load of pressure and weight over the entire surface of a joint. When cartilage is damaged, 
the smooth gliding motion that bones were once able to achieve is disrupted, and 
movement becomes painful. If a joint experiences improper alignment, excessive weight, 
overuse, or injury, cartilage wears away. Once damaged, cartilage lacks a direct blood 
supply, resulting in a limited ability of the tissue to repair itself. If damaged cartilage is 
left untreated, disease can spread throughout the entirety of the tissue causing
degradation, followed by pain, limited ability of joint movement, and possibly the 
contraction of osteoarthritis. Orthopedic researchers are continuing to search for new 
ways to treat damaged cartilage. Currently, there have been many advances in the
surgical treatment of articular cartilage defects. However, newer techniques involving
tissue-engineered cartilage hold some promise, but their effectiveness and long-term 
outcomes have not been currently established.
The knee is a hinge joint that is formed by two bones and held in place by several 




    
   
 







cartilage. The synovial membrane surrounds and protects the knee joint, and also 
functions to produce synovial fluid. Synovial fluid acts as a lubricant for our joints and is 
responsible for providing cartilage with its slippery surface. The small amount of fluid 
that the synovial membrane provides allows forces on joints to not be directly applied to
bones. Cartilage receives nutrients and oxygen, and removes carbon dioxide and waste 
from cells within surrounding cartilage by diffusion through the synovial fluid. When the 
joint is loaded, fluid carrying waste and carbon dioxide is forced out of cartilage. Once
relieved, the fluid is allowed to diffuse back into the tissue, carrying oxygen and nutrients 
with it.














    
    
   
 
 
    
Articular Cartilage Injury
Cartilage injuries and damage can occur from trauma, disease, or repetitive
loading to the joint, and in turn, articular cartilage tissue will lose partial or complete 
function. Without a direct blood supply, cartilage is incapable of initiating the healing
process. Articular cartilage trauma injuries can occur either as a chondral fracture or an 
osteochondral fracture. Chondral fractures occur when there is trauma to the joint surface
usually in the form of a tear, but which does not affect the underlying subchondral bone. 
Osteochondral fractures occur when there is trauma to the joint surface that affects the 
underlying subchondral bone. If left untreated, these joint surface fractures can become 
progressively worse causing degradation of articular cartilage tissue and possibly the
contraction of osteoarthritis [3]. Osteoarthritis, or degenerative joint disease, is a joint 
disease caused by cartilage degeneration and loss in a joint, and those who suffer from 
the disease experience pain and stiffness [4].
Composition
Articular cartilage is composed of cells known as chondrocytes and is surrounded 
by a complex extracellular matrix (ECM) (Figure 1.2). Chondrocytes account for only
1% of the volume of articular cartilage, and the ECM accounts for the remaining 99%.
Water makes up as much as 80% of articular cartilage tissue weight. The remaining solid 
fraction of the tissue is composed of structural macromolecules. Collagen, proteoglycans,
and noncollagenous proteins are the structural macromolecules present in articular 











   
   
 




   
 
Only one type of cell, the chondrocyte, is present in articular cartilage. 
Chondrocytes are formed by a chondroblast, which originates from a MSC. Chondrocytes 
are highly specialized cells responsible for producing and maintaining the ECM. These
cells are sparsely distributed and embedded throughout the ECM. Chondrocytes play an 
essential role in maintaining the tissue by synthesizing all matrix components. As the 
cells secrete matrix material, chondrocytes become confined into small chambers called 
lacunae. The lacunae separate chondrocytes from one another, preventing interaction 
between cells in the ECM. Because articular cartilage is avascular, chondrocytes receive 
nutrients and oxygen through diffusion from the synovial fluid into the cartilage matrix.
The articular cartilage ECM consists of tissue fluid and the framework of 
structural macromolecules. The interaction between the tissue fluid and the structural
macromolecules provides articular cartilage with its stiffness and resilience [5, 6]. Water
contributes to the majority of the wet weight of articular cartilage tissue fluid. Articular
cartilage tissue fluid also includes gases, small proteins, metabolites, and high 
concentrations of cations. Some water is capable of moving freely in and out of the
tissue. However, the volume, concentration, and behavior of water at a particular time in 






   
  
 





Figure 1.2 Illustration depicting the composition of articular cartilage. From (bidmc.org)
There are three classes of structural macromolecules present in articular cartilage,
collagen, proteoglycans and non-collagenous proteins. These structural macromolecules
exist throughout articular cartilage in varying concentrations and contributions to the 
tissue. Of the total 20% to 40% contributed wet weight, structural macromolecules 
account for the following, collagen (10%), proteoglycans (10%), and noncollagenous 
proteins (5% - 10%).
Collagen configuration can be described as a fibrous protein composed of three
chains of amino acids that take that shape of triple helix. Making up approximately 60%
of the dry weight of cartilage; collagen functions to create a framework housing the other





   
     
    
 
 
    




   
    
 





   
  
articular cartilage, and accounts for 90% - 95% of the collagen content present in the 
tissue. Type II collagen fibers cross-link to create the major support network for the 
ECM, giving articular cartilage its tensile strength. Collagen types III, VI, IX, X, XI, XII, 
and XIV are also present in articular cartilage tissue in smaller amounts.
Proteoglycans can be described as macromolecules composed of a central core
protein with highly fixed negatively charged glycosaminoglycan (GAG) subunits 
attached to form a bottlebrush-like structure. The two main types of GAG found in 
articular cartilage are chondroitin sulfate and keratin sulfate. Proteoglycans can exist as
individual monomers or also bind to a hyaluronic acid backbone by link proteins to form 
a macromolecule, the aggrecan. The aggregating proteoglycans function to help maintain 
the fluid within the ECM and the concentration of electrolytes in the tissue fluid [7]. Due
to their highly negative charge, GAG molecules are extremely hydrophilic and can trap 
large amounts of water within the ECM, providing articular cartilage with its definitive
elastic behavior. The large size of the aggrecan function to trap proteoglycans within the
network of collagen, and in turn provides articular cartilage tissue with its stiffness.
Figure 1.3 illustrates the structure of the proteoglycan macromolecule.
Non-collagenous proteins and glycoproteins contribute 15% to 20% of the dry
weight of articular cartilage. For the purposes of this study, we will concentrate on only
one of these non-collagenous proteins, cartilage oligomeric matrix protein (COMP). 
COMP is an acidic protein and is concentrated within the territorial matrix of the
chondrocyte. COMP appears to be present only within cartilage, and has the capacity to 
bind to chondrocytes [8, 9]. Previous studies support the belief that COMP plays a role in 















cell movement and attachment [10, 11]. However, the precise function of COMP remains 
unknown.
Figure 1.3 Illustration depicting the components of the ECM of articular cartilage. From 
(arthritis-research.com)
Tissue Engineering
The engineering of living tissue, tissue engineering, can be defined as the use of 
living cells, manipulated through their extracellular environment to develop biological 
substitutes for implantation into the body and/or to foster the remodeling of existing
tissue [12]. The purpose of tissue engineering is to repair, replace, enhance, or maintain 
the function of a particular tissue or organ. Current surgical therapies in articular cartilage
repair have yielded unsatisfactory and short-term results in the method of healing
cartilage tissue. Tissue engineering is a fast-growing area of research that may serve as an 
8
  
       



















alternative approach for providing articular cartilage tissue repair or replacement without
the negative shortcomings associated with current therapies. Advancements in science
have brought tissue engineering to the forefront of the scientific research community.
However, due to its complex composition and unique properties, cartilage is considered 
one of the most difficult tissues to recreate.
Cell Source
MSCs are unspecialized, undifferentiated cells that are characterized by their 
ability for long-term self-renewal and potential to produce different cell types in 
differentiation. Ernest A. McCulloch and James E. Till first identified bone marrow
derived MSCs in the 1960s as being a clonal source of cells [13]. MSCs are capable of
dividing and replicating themselves over long periods of time through a process called
proliferation.
Additional work, in the 1970s and 1980s, conducted by Friedenstein, et al.,
expanded upon the potential of MSCs by demonstrating their capacity for multilineage
differentiation [14, 15]. MSCs lack any tissue-specific structures that allow the cell to 
perform specialized functions. Through a process called differentiation MSCs can give
rise to tissue specific cells. MSCs have proven to demonstrate the capability to 
differentiate into cells of multiple lineages, including chondrocyte, osteoblast, myoblast, 
adipocyte, and fibroblast [16-23]. Figure 1.4 illustrates the mechanism by which MSCs 
undergo proliferation and differentiation. These characteristics have made MSCs a 
popular cell source among current experimental approaches to articular cartilage tissue 












of MSCs to a desired mature cell, which frequently involves addition of a transforming
growth factor to the culture medium.
Chondrogenesis is the term used to describe the process by which a stem cell is 
differentiated into a mature chondrocyte. However, MSCs can only undergo
chondrogenic differentiation when induced by various intrinsic and extrinsic factors. 
Growth factors represent a group of biologically active polypeptides produced by the 
body, which can stimulate cell proliferation and differentiation to a particular phenotype.
In articular cartilage, growth factors control homeostasis and development [24]. Both 
MSCs and growth factors are promising tools in the ever-evolving field of cartilage tissue 
engineering. However, determining the growth factor, growth factor concentration, and 












   
Figure 1.4 Illustration depicting the cellular proliferation and chondrogenic
differentiation mechanism of MSCs. From [25].
Growth Factors
Numerous studies have reported efficient chondroinduction of MSCs using either 
transforming growth factor beta-1 (TGF-β1) [26-29] or TGF-β3 [30-36]. For example, 
adult stem cells from bone marrow cultured in defined medium containing 10 ng/ml 




     
 
   




   
 
  
     
 
     
 
   
 
  
over a 14-day period [34]. In a head-to-head comparison, TGF-β3 was found to stimulate 
expression of cartilage ECM components to a greater extent than TGF-β1 [30].
A potential drawback of the use of TGF-β3 for chondroinduction is that it may
stimulate continued differentiation towards a hypertrophic phenotype as evidenced by
increasing type X collagen expression [30]. By contrast, bone morphogenetic protein-13 
(BMP-13) has been shown to support chondrogenesis in C3H10T1/2 cell cultures, but not 
terminal differentiation to hypertrophic chondrocytes [37]. A separate study using
articular chondrocytes confirmed that BMP-13 does not promote hypertrophy [38]. The
presence of type X collagen, only near the cells of the calcified cartilage zone of articular 
cartilage and the hypertrophic zone of growth plate, suggests that it has a role in cartilage
mineralization.
BMP-13 was first identified and isolated as a component of bovine cartilage [39].  
BMP-13, also known as cartilage-derived morphogenetic proteins-2 (CDMP-2), and the 
human homolog of mouse Gdf-6, belong to the TGF-β superfamily. Members of the 
superfamily are essential for the formation of cartilaginous tissue during early limb 
development [39, 40]. Previous reports (38, 41-44) have demonstrated the effects of 
BMP-13 in osteochondrogenesis using recombinant or adenovirus-mediated human 
BMP-13 (hBMP-13), and have also demonstrated that BMP-13 promoted chondrogenic 
differentiation in a variety of cells [41] and positively regulated growth and maintenance
of articular cartilage [42]. However, two studies have reported that BMP-13 induced 
neotendon/ neoligament formation in vivo [45, 46]. The biological effects of BMP-13 
remain controversial, and no studies have examined the effects of overexpression of





The purpose of the current study was to determine the potential for BMP-13 to 












   
  







   
 




In order to determine the effect of growth factor BMP-13 on chondrogenesis of 
human bone marrow-derived MSCs, a pellet culture experiment was designed in order to 
compare the effects of growth factors, TGF-β3 and BMP-13. Four experimental groups 
were formed: a control group, a group supplemented with TGF-β3, a group supplemented 
with BMP-13 and a group supplemented with both TGF-β3 and BMP-13. The experiment 
was conducted over a 21-day period. The pattern of expression of key ECM components,
as well as components known to stimulate a hypertrophic phenotype, were studied in 
order to develop a better understanding of the steps in the pathway leading from 
undifferentiated stem cell to mature chondrocyte.
Cell Source
Human multipotential marrow stromal cells (21 year-old female) frozen at 
passage 1 were provided by the Texas A&M Health Science Center College of Medicine
Institute for Regenerative Medicine. These cells were extensively characterized and 
confirmed to meet the minimal criteria which define human MSCs as established by the 
Mesenchymal and Tissue Stem Cell Committee of the International Society for Cellular
14
  














   
  
  





Therapy [47]. These criteria include expression of the CD105, CD73 and CD90 surface
molecules and display of multilineage differentiation in vitro.
Cells were thawed into expansion medium (Dulbecco’s modified Eagle Medium
(DMEM) containing 10% fetal bovine serum (FBS) and 1% antibiotic antimycotic
solution) and plated at approximately 5×103 cell/cm2 in two T-175 flasks. Cultures were
maintained at 37°C in a humidified environment containing 95% air and 5% CO2, and the 
cells were subcultured prior to reaching confluence. When passage 3 cells approached 
confluence, they were detached using trypsin, which was then neutralized by the addition 
of 10% FBS. RNA was isolated from five independent samples of these monolayer 
expanded cells to serve as a baseline for calculating subsequent changes in gene
expression. These cells will be referred to as undifferentiated MSCs.
Pellet Culture
After centrifugation and aspiration of trypsin, cells were resuspended in differing
media from which one control and three experimental groups were formed. Control group 
cells were resuspended in expansion medium. The three experimental groups were BMP-
13, TGF-β3, and (TGF-β3→BMP-13). Cells in the BMP-13 group were resuspended in
defined chondrogenic medium (DCM) containing 10 ng/ml BMP-13, and those in the
remaining two experimental groups were resuspended in DCM plus 10 ng/ml TGF-β3. 
DCM consisted of high-glucose DMEM, 1% ITS+Premix (6.25 µg/mL insulin, 6.25 
µg/mL transferrin, 6.25 µg/mL selenious acid, 1.25 mg/mL bovine serum albumin, and 
5.35 µg/mL linoleic acid), 0.1 µM dexamethasone, 50 mg/mL ascorbate-2 phosphate, 1 
mM sodium pyruvate, 40 µg/mL L-proline, 1% antibiotic-antimycotic solution (100 
15
  
   










U/mL penicillin, 0.1 mg/mL streptomycin, and 0.25 µg/mL amphotericin B). Each cell
suspension was evenly divided among 36 15-mL conical polypropylene centrifuge tubes 
so that each tube contained approximately 4×105 cells in 0.75 ml of medium. Tubes were
centrifuged at 500g for 3 min and the resulting pellet cultures maintained in culture at 37
°C in a humidified atmosphere containing 95% air and 5% CO2. Figure 2.1 displays the 
gross morphology of a pellet culture in phosphate buffered saline (PBS) at the final day
of the experiment.
Figure 2.1 Gross morphology of pellet culture in PBS.
The medium was replaced every 3-4 days for 21 days. After 3 days of culture in 









     
   
   
   






   
   
 
     
 
  
     
with DCM plus 10 ng/ml BMP-13, in which the cells were cultured for remainder of the 
experiment. Chondroinduction was evaluated based on gene expression, histology, and 
immunohistochemistry of pellets following 3, 10, and 21 days of culture. The medium 
content for each group over the course of the experiment is displayed in Table 2.1.
Table 2.1   Groups defined according to medium content at each experimental time point.
Group Name Day 0 - Day 3 Day 3 - Day 21
Group I Expansion Medium Expansion Medium
Group II DCM + TGF-β3 DCM + TGF-β3
Group III DCM + BMP-13 DCM + BMP-13
Group IV DCM + TGF-β3 DCM + BMP-13
Histological and Immunocytochemical Analysis
In order to evaluate the chondrogenic differentiation of the pellets, samples grown 
at three time points were extracted and immediately fixed in 10% buffered formalin. The
pellets were then infiltrated and embedded in paraffin and sectioned to slides (University
of Alabama-Birmingham’s Center for Metabolic Bone Disease). Sections were stained
with Hemotoxylin and Eosin (H&E) to evaluate the internal structure or Toluidine Blue
to evaluate proteoglycan concentration.
Additional sections were immunostained for detection of collagen types II and X. 




   
   
 
   
 
 





      
  





    
polyclonal antibody from MD Bioproducts (St. Paul, MN) and mouse anti-pig Collagen 
X monoclonal antibody from Abcam (Cambridge, MA). Pellet sections for
immunohistochemistry were deparaffinized and rehydrated in xylene and graded ethanol, 
respectively. GAG removal and collagen exposure were performed by incubating slides 
in hyaluronidase (2 mg/ml in tris buffered saline) for 25 minutes at 95°C. Antigen 
retrieval was then performed by incubating slides in pronase (0.5mg/ml in PBS) for 10 
minutes at 95°C. Subsequent incubations were all at room temperature, beginning with 
the primary antibody for one hour. Primary antibody diluted 1:10 in PBS with 1% bovine 
serum albumin was applied to sections and allowed to infiltrate for one hour at room 
temperature. Following the primary antibody, slides were stained following instructions 
from the SuperPicture 3rd Gen IHC Detection Kit (Invitrogen Corp., Frederick, MD). 
Multiple washes with PBS were performed between all incubations. Type II collagen and 
type X collagen positively stain dark orange to brown in color. High-resolution images 
were taken with the Leica DM 2500 microscope (Leica Microsystems Inc., Bannockburn,
IL) in transmitted light mode under the same exposure for all slides.
Glycosaminoglycan and DNA Measurement
Three pellets from each group at every time point were digested in 1% papain and 
50 mM sodium acetate at 60°C overnight. The total DNA content of the digestate was 
measured using the Hoechst method. Aliquots of the digestate were added to 0.1 μg/ml 
bisBenzimide solution in Fluorescent Assay Buffer, and fluorescence intensity was 


















   
Corporation, Madison, WI). DNA content was obtained from a standard curve prepared 
with calf thymus DNA.
Total GAG content from the same papain digestate used in DNA analysis was 
quantified using the Blyscan Glycosaminoglycan Assay kit (Biocolor, Newtonabby, 
Northern Ireland), based on dimethyl methylene blue dye binding. The absorbance at 656 
nm was measured with a BioTek μQuant Microplate Spectrophotometer (BioTek 
Instruments, Winooski, VT), and GAG concentration was calculated using a standard 
curve established from a chondroitin sulfate standard.
RNA Preparation and RT-PCR
Total RNA was prepared from undifferentiated MSCs (5 independent samples) 
and from pellets (3 per experimental group) cultured for 3, 10, and 21 days. The
expression of selected genes was determined by TaqMan® qRT-PCR using pre-designed 
and validated probe/primer sets (Asuragen Inc., Austin, TX). Genes of interest were
aggrecan, cartilage oligomeric matrix protein (COMP), and collagen types I, II, and X.
Total RNA (200ng) was reverse transcribed in a total reaction volume of 20 µL.  
Assuming 100% cDNA synthesis efficiency, 10ng total RNA equivalent cDNA was 
added to the master mix for a final volume of 15 µL in each PCR well. All amplifications 
were performed in triplicate on a validated Applied Biosystems 7900HT real-time 
thermocycler. PCR was initialized by incubation at 95°C for 10 m, followed by 40 cycles 
of amplification: 95°C for 15 s, then 60°C for 1 m. Beta-2-microglobulin was used as a 
normalizer gene for ΔCT calculations and the undifferentiated MSCs used as a calibrator 
for calculation of fold changes by the ΔΔCT method.
19
  















   




Results of the RT-PCR data were represented as CT values. CT can be defined as 
the threshold cycle number for PCRs at which an amplified product was first detected 
[48]. The average CT was calculated for the normalizer gene, beta-2-microglobulin, and 
treatment group samples, and ΔCT was determined as (the mean of the triplicate CT 
values for the normalizer gene) minus (the mean of the triplicate CT values for treatment 
group samples). ΔΔCT can be calculated by taking the difference between ΔCT of
treatment group sample and ΔCT of undifferentiated MSCs from Day 0. Fold change can 
be described as a differential expression in the normalizer gene of a treatment group 
sample compared to the Day 0 undifferentiated MSCs counterpart and calculated by 2 -
ΔΔCT [48].
Follow-Up Experiments
Based on results of the primary experiment described above, two follow-up 
experiments were performed to further clarify the effectiveness of BMP-13 for sustaining
chondroinduction of primary human MSCs through the use of RT-PCR analysis. The first 
follow-up experiment was designed to determine whether BMP-13 was responsible for
any of the elevation in chondrocyte gene markers after 3 days of chondroinduction by
TGF-β3. The initial gene expression experiment was repeated using cells from a 24 year-
old male donor, but the only two experimental groups were (TGF-β3→BMP-13) and a
new group, (TGF-β3→DCM). At the same time the TGF-β3-containing medium was 
replaced with the BMP-13-containing medium in the former group, DCM without any
growth factor replaced the medium and growth factor in the latter group. The second 








    
 
the TGF-β3-induced upregulation of type X collagen RNA. The initial gene expression 
experiment was repeated using cells from a 22-year old male donor. Again, only two 
experimental groups were included, TGF-β3 and a new group, (TGF-β3→Combination), 
in which 10 ng/ml BMP-13 was added to the TGF-β3 containing medium after Day 3.
Statistical Analysis
All data were analyzed by using SPSS for Windows software, version 12.0 
(SPSS, Chicago, IL). Numerical results are expressed as the mean ± standard deviation. 
A one-way analysis of variance and LSD posthoc test (α=0.05) were performed to test for


















Histological and Immunocytochemical Evaluation
H&E staining were done in order to analyze the cellular structure of the samples. 
The stained sections for each group display a loss in cellular content over time. At each 
progressive time point for all treatment groups following Day 3, cellular debris collected 
in the center of the sphere of each of the pellet constructs. However, the perimeter of each 
spherical section indicates live cellular content from the appearance of cell nuclei and 

















Histological evaluation shows an intense staining with toluidine blue in all 
treatment groups across time, indicating an ECM rich in proteoglycans. Following the 
initial time point, a higher intensity of toluidine blue can be seen in the groups at both 
Day 10 and Day 21 compared to that of Day 3. Groups do not seem to show a distinct 
staining compared to one another. However, groups do show a higher staining intensity
from Day 3 to Day 10. Figure 3.2 displays sections stained for toluidine blue for each 










   
  
 
   
 
  




     
 
 
Immunocytochemical analysis of type II collagen shows a distinct staining in 
Group II and Group IV at different time points, indicating the presence of type II
collagen. Group I at Day 3 stains relatively light for type II collagen, and no change is 
exhibited over the remaining time points. Group II type II collagen staining at Day 3 
displays a positive staining for type II collagen, and such fibers can be seen. Group II
displays no change in intensity of type II collagen staining over time. Group III at Day 3 
stains very light in color, indicating little or no existence of type II collagen. Group III
remains light in staining over the course of the experimental time points. Group IV at 
Day 3 displays a positive staining for type II collagen, and such fibers can be seen. At 
Day 10, there is a dramatic decrease in type II collagen staining intensity for Group IV. 
From Day 10 to Day 21, there is no relative change in type II collagen staining intensity
for Group IV. Figure 3.3 displays sections immunostained for type II collagen for all












     
  
 
   
  
    





Immunocytochemical analysis of type X collagen shows a distinct staining in 
Group II and Group IV at different time points, indicating the presence of type X 
collagen. Group I at Day 3 shows a light stain indicating no existence of type X collagen. 
Over time, the staining intensity for Group I remain unchanged with no type X collagen 
present over the course of the experiment. Group II displays an intense type X collagen 
stain at Day 3, indicating the presence of type X collagen. At Day 10, Group II type X 
collagen stain appears more intense. From Day 10 and Day 21, the existence of type X 
collagen is even more prevalent in the dark staining color and fibers. Group III at Day 3 
shows a light stain indicating the little or no presence of type X collagen. Group III type
X collagen staining intensity remains unchanged with no presence of type X collagen 
over time. Group IV displays an intense type X collagen stain at Day 3, indicating the 
presence of the fiber. However, at Day 10, there is a dramatic decrease in type X staining
intensity, indicating a major loss in the fiber expression between time points. At Day 21, 
type X collagen staining remains light in color similar to that of the previous time point
for Group IV. Figure 3.4 displays sections immunostained for type X collagen for each 

























Total GAG content (normalized to DNA) for the treatment groups at each time 
point is displayed in Figure 3.5. GAG content for Group I at Day 3 averages a 
(2.35±0.93) mean across six pellets. At Day 10, Group I undergoes a significant increase
in mean GAG content at (4.21±1.15) across pellets. Between Day 10 and Day 21, Group 
I exhibits no significant change in GAG content averaging a mean of (2.96±1.10) across 
pellets. GAG content for Group II at Day 3 averages a (1.31±0.24) mean across six
pellets. At Day 10, Group II undergoes a significant increase in mean GAG content at 
(3.98±1.21) across pellets. Between Day 10 and Day 21, Group II exhibits no significant 
change in mean GAG content averaging a mean of (3.42±0.93) across pellets. GAG
content for Group III at Day 3 averages a (1.85±0.62) mean across six pellets. At Day 10, 
Group III undergoes a significant increase in mean GAG content at (4.36±1.17) across 
pellets. Between Day 10 and Day 21, Group III exhibits no significant change in mean 
GAG content averaging a mean of (2.58±0.64) across pellets. GAG content for Group IV 
at Day 3 averages a (1.42±0.22) mean across five pellets. At Day 10, Group IV 
undergoes a significant increase in mean GAG content at (3.93±0.92) across pellets. 
Between Day 10 and Day 21, Group IV exhibits no significant change in mean GAG 
content averaging a mean of (3.49±1.01) across pellets.
At Day 3, Group I demonstrated a significantly higher mean GAG content 
compared to that of Group II and Group IV. Group III was not considered significantly
different from any of the other groups. GAG content for all groups did not significantly













3 by 135% (4.12±1.06 vs. 1.75±0.69 μg/μg, n = 6 per group). From Day 10 to Day 21, 
groups again exhibited no significant difference when compared to one another.
Figure 3.5 Total GAG content averaged across pellets for each Group over time.
DNA content for Group I at Day 3 averages a (737.22±38.95) mean across six
pellets. At Day 10, Group I undergoes a significant decrease in mean DNA content at 
(453.37±32.35) across pellets. Between Day 10 and Day 21, Group I exhibits no 
significant change in DNA averaging a mean of (431.32±39.32) across pellets. DNA
content for Group II at Day 3 averages a (739.85±36.90) mean across six pellets. At Day













    
  
    
    
 
 
across pellets. Between Day 10 and Day 21, Group II exhibits no significant change in 
DNA averaging a mean of (305.06±17.33) across pellets. DNA content for Group III at 
Day 3 averages a (785.27±100.25) mean across six pellets. At Day 10, Group III
undergoes a significant decrease in mean DNA content at (438.17±19.01) across pellets. 
Between Day 10 and Day 21, Group III exhibits no significant change in DNA averaging
a mean of (375.44±21.28) across pellets. DNA content for Group IV at Day 3 averages a 
(808.01±29.99) mean across five pellets. At Day 10, Group IV undergoes a significant 
decrease in mean DNA content at (341.50±53.31) across pellets. Between Day 10 and 
Day 21, Group IV exhibits no significant change in DNA averaging a mean of 
(307.97±29.88) across pellets.
At Day 3, treatment groups exhibited no significant difference between one
another. DNA content for Group I and Group III displayed significantly higher mean 
values than that of Group II and Group IV at Day 10. From Day 10 to Day 21, Group I
and Group III again expressed a higher mean DNA content than that of groups Group II
and Group IV. However, Group I exhibited a significantly higher mean DNA content 
than that of all groups. On Day 10 and Day 21, pellets from all groups contained about 
50% of the DNA at which they had contained on Day 3. Total DNA content for the 










   
  
  
Figure 3.6 Total DNA content averaged across pellets for each Group over time.
Following statistical analysis for each gene’s mean fold change, the significant 
comparison between treatment groups over time could be determined. The data is 
presented as the fold change in target gene expressions for all treatment groups and is 
relative to five independent samples of undifferentiated MSCs from Day 0.
Aggrecan expression for Group I at Day 3 averages a (-11.99±1.24) mean fold 
change across pellets. At Day 10, aggrecan expression for Group I experiences a 
significant increase in mean fold change at (-7.61±2.43). Between Day 10 and Day 21, 
aggrecan expression increases but does not experience a significant change at a (-




    
  

















averages a (-3.40±1.83) mean fold change across pellets. At Day 10, aggrecan expression 
for Group II experiences an increase in mean fold change at (-1.34±0.42). Between Day
10 and Day 21, aggrecan expression significantly increases at a (2.86±0.72) mean fold 
change for Group II. Aggrecan expression for Group III at Day 3 averages a (-4.12±1.59) 
mean fold change across pellets. At Day 10, aggrecan expression for Group III
experiences a decrease in mean fold change at (-11.07±6.10). Between Day 10 and Day
21, aggrecan expression significantly increases at a (1.14±0.09) mean fold change for 
Group III. Aggrecan expression for Group IV at Day 3 averages a (-3.12±1.35) mean fold 
change across pellets. At Day 10, aggrecan expression for Group IV experiences a 
significant decrease in mean fold change at (-7.05±2.06). Between Day 10 and Day 21, 
aggrecan expression significantly increases at a (-2.78±1.06) mean fold change for Group 
IV. Group I and Group II aggrecan expression significantly differ between Day 3 and 
Day 21.
At Day 3, aggrecan expression is significantly lower for Group I compared to that 
of the other treatment groups. Group II and Group III exhibit the only significant 
difference in mean fold change relative to aggrecan expression at Day 10, with Group II
having a significantly higher mean fold change value. At Day 21, Group I aggrecan 
expression experiences a significantly lower mean fold change compared to that of the
other treatment groups. Also, Group II has a significantly higher mean fold change than 
all groups at Day 21. All treatment groups at Day 21 experience a significant difference
from all other treatment groups with respect to aggrecan expression of mean fold change.








    
  
  




Figure 3.7 Total aggrecan mean fold change in pellets over time for initial experiment.
COMP expression for Group I at Day 3 averages a (1.14±0.21) mean fold change
across pellets. At Day 10, COMP expression for Group I experiences a decrease in mean 
fold change at (-2.03±0.07). Between Day 10 and Day 21, COMP expression experiences 
a significant increase at a (4.43±3.83) mean fold change for Group I. COMP expression 
for Group II at Day 3 averages a (76.57±22.54) mean fold change across pellets. At Day
10, COMP expression for Group II experiences a significant increase in mean fold 
change at (728.70±172.75). Between Day 10 and Day 21, COMP remains relatively
unchanged at a (675.89±231.69) mean fold change for Group II. COMP expression for 
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Group III at Day 3 averages a (-0.19±1.49) mean fold change across pellets. At Day 10, 
COMP expression for Group III experiences a decrease in mean fold change at (-1.33 
±0.36). Between Day 10 and Day 21, COMP expression significantly increases at a mean 
fold change (7.11 ±0.87) for Group III. COMP expression for Group IV at Day 3 
averages a (117.54±15.24) mean fold change across pellets. At Day 10, COMP
expression for Group IV experiences a significant decrease in mean fold change at 
(48.28±15.28). Between Day 10 and Day 21, COMP expression decreases at a 
(22.62±13.37) mean fold change for Group IV. Only Group I COMP expression did not
significantly differ between Day 3 and Day 21.
At Day 3, COMP expression is significantly lower for Group I and Group II
compared to Group II and Group IV mean fold change. COMP expression for Group II
expresses a significantly higher mean fold change compared to the other groups at Day
10. Group II COMP expression, again at Day 21, experiences a significantly higher mean 
fold change compared to the remaining groups. Total COMP mean fold change for the 






   
    
      
  





Figure 3.8 Total COMP mean fold change in pellets over time for initial experiment.
Type I collagen expression for Group I at Day 3 averages a (-1.49±0.28) mean 
fold change across pellets. At Day 10, type I collagen expression for Group I experiences 
an increase in mean fold change at (-0.34±1.22). Between Day 10 and Day 21, type I
collagen expression experiences a significant increase at a (1.88±0.30) mean fold change
for Group I. Type I collagen expression for Group II at Day 3 averages a (2.84±0.28)
and Day 21, type I collagen increases at a (8.27±1.24) mean fold change for Group II. 
Type I collagen expression for Group III at Day 3 averages a (1.31±0.40) mean fold 
mean fold change across pellets. At Day 10, type I collagen expression for Group II
experiences a significant increase in mean fold change at (6.17±1.45). Between Day 10 
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change across pellets. At Day 10, type I collagen expression for Group III experiences an 
increase in mean fold change at (1.71±0.17). Between Day 10 and Day 21, type I
collagen expression significantly increases at a mean fold change (5.12±0.30) for Group 
III. Type I collagen expression for Group IV at Day 3 averages a (2.56±0.45) mean fold 
change across pellets. At Day 10, type I collagen expression for Group IV experiences an 
increase in mean fold change at (3.57±0.24). Between Day 10 and Day 21, type I
collagen expression significantly increases at a (4.65±0.78) mean fold change for Group 
IV. All groups type I collagen expression differ significantly between Day 3 and Day 21.
At Day 3, type I collagen expression is significantly lower for Group I compared 
to the remaining groups.  Group II and Group IV also exhibit a significantly higher mean 
fold change than Group III in type I collagen expression at Day 3. Again, Group I type I
collagen expression exhibits a significantly lower mean fold change, and Group II
exhibits a significantly higher mean fold change compared to remaining groups at Day
10. Group IV also expresses a significantly higher type I collagen expression than Group 
III. Group II, Group III and Group IV type I collagen expression, at Day 21, experiences 
a significantly higher mean fold change compared to that of the remaining group, Group 
I. However, Group II has a significantly higher mean fold change type I collagen 
expression than all groups at Day 21. Total type I collagen mean fold change for the 







   
     
 
  
   
  
 
   
      
Figure 3.9 Total type I collagen mean fold change in pellets over time for initial 
experiment.
At Day 10, type II collagen expression for Group I experiences a mean fold 
change at (2.15±0.55). Between Day 10 and Day 21, type II collagen expression 
experiences an increase at a (2.72±1.36) mean fold change for Group I. Type II collagen 
expression for Group II at Day 3 averages a (11.87±8.72) mean fold change across 
pellets. At Day 10, type II collagen expression for Group II experiences an insignificant 
decrease in mean fold change at (9.33±7.97). Between Day 10 and Day 21, type II
collagen remains relatively unchanged at (8.95±4.03) mean fold change for Group II. The
type II collagen expression for Group III at Day 3 averages a (0.37±1.42) mean fold 




    
   
    
 
    
   
 
   
    
   
    
 
 
experiences an increase in mean fold change at (2.24±0.99). Between Day 10 and Day
21, type II collagen expression decreases at a mean fold change (0.46±1.76) for Group 
III. The type II collagen expression for Group IV at Day 3 averages a (14.67±4.57) mean 
fold change across all pellets. At Day 10, type II collagen expression for Group IV 
experiences a significant decrease in mean fold change at (4.83±1.73). Between Day 10 
and Day 21, type II collagen expression decreases at a (2.76±0.604) mean fold change for 
Group IV. Group IV type II collagen expression differs significantly between Day 3 and 
Day 21. Also, all treatment groups exhibit no significant change in type II collagen 
content from Day 10 to Day 21.
At Day 3, type II collagen expression is significantly lower for Group III
compared to the remaining groups present. Type II collagen expression does not exhibit a 
significantly different mean fold change among all groups at Day 10. Group II type II
collagen expression experiences a significantly higher mean fold change compared to that 
of the remaining groups at Day 21. Total type II collagen mean fold change for the 
















Figure 3.10 Total type II collagen mean fold change in pellets over time for initial 
experiment.
Type X collagen expression for Group I at Day 3 averages a (-3.53±0.79) mean 
fold change across pellets. At Day 10, type X collagen expression for Group I
and Day 21, type X collagen expression experiences a significant increase at a 
collagen expression for Group II experiences an increase in mean fold change at 
experiences a significant decrease in mean fold change at (-12.20±2.45). Between Day 10 
(0.56±3.93) mean fold change for Group I. Type X collagen expression for Group II at 
Day 3 averages a (449.57±70.27) mean fold change across pellets. At Day 10, type X 
(547.52±17.84). Between Day 10 and Day 21, type X collagen significantly increases at a
(875.31±177.72) mean fold change for Group II. Type X collagen expression for Group 
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III at Day 3 averages a (3.41 ±1.59) mean fold change across pellets. At Day 10, type X 
collagen expression for Group III remains relatively unchanged in mean fold change at 
(5.77±3.15). Between Day 10 and Day 21, type X collagen expression significantly
increases at a mean fold change (44.45±12.71) for Group III. Type X collagen expression 
for Group IV at Day 3 averages a (361.23±78.19) mean fold change across pellets. At
Day 10, type X collagen expression for Group IV experiences a significant decrease in 
mean fold change at (20.86±3.56). Between Day 10 and Day 21, type X collagen 
expression remains relatively unchanged at a (44.63±27.65) mean fold change for Group 
IV. Group II, Group III, and Group IV type X collagen expression differ significantly
between Day 3 and Day 21.
At Day 3, type X collagen expression is significantly higher for Group II and 
Group IV compared to that of Group I and Group III. Type X collagen expression for 
Group II expresses a significantly higher mean fold change compared to the other groups 
at Day 10. Again, Group II type X collagen expression experiences a significantly higher 
mean fold change compared to that of the remaining groups at Day 21. Total type X 
















The first follow-up experiment was designed to determine whether BMP-13 was 
responsible for any of the elevation in chondrocyte gene markers after 3 days of 
chondroinduction by TGF-β3, with only two experimental groups present, (TGF-
β3→BMP-13) and (TGF-β3→DCM). Total RNA was prepared from undifferentiated 
MSCs and also from pellets cultured at days 3 and 10 using the Qiagen RNeasy mini kit. 
RT-PCR analysis followed the same experimental outline as discussed previously.  Group 











expression. At Day 10, (TGF-β3→BMP-13) undergoes a significant decrease in aggrecan 
expression at a mean fold change of (-114.14±17.26). Group (TGF-β3→DCM) exhibits a 
mean (-14.56±4.07) fold change at Day 3 aggrecan expression. At Day 10, (TGF-
β3→DCM) undergoes a significant decrease in aggrecan expression at a mean fold 
change of (-105.95±0.00). At Day 3 and Day 10, Group (TGF-β3→BMP-13) and Group 
(TGF-β3→DCM) do not exhibit a significant difference in aggrecan expression. Total 
aggrecan mean fold change for the groups at each time point for the first follow-up 
experiment is displayed in Figure 3.12.







   
 
 
Group (TGF-β3→BMP-13) exhibits a mean (-4.44±0.37) fold change at Day 3 
COMP expression. At Day 10, (TGF-β3→BMP-13) undergoes a significant decrease in 
COMP expression at a mean fold change of (-43.28±3.62). Group (TGF-β3→DCM) 
exhibits a mean (-4.81±0.71) fold change at Day 3 COMP expression. At Day 10, (TGF-
β3→DCM) undergoes a significant decrease in COMP expression at a mean fold change
of (-37.55±9.55). At Day 3 and Day 10, Group (TGF-β3→BMP-13) and Group (TGF-
β3→DCM) do not exhibit a significant difference in COMP expression. Total COMP
mean fold change for the groups at each time point for the first follow-up experiment is 






   
   





Figure 3.13 Total COMP mean fold change in pellets over time for first follow-up 
experiment.
Group (TGF-β3→BMP-13) exhibits a mean (0.24±1.51) fold change at Day 3 
type II collagen expression. At Day 10, (TGF-β3→BMP-13) remains relatively
unchanged in type II collagen expression at a mean fold change of (1.11±2.21). Group 
(TGF-β3→DCM) exhibits a mean (-2.29±0.82) fold change at Day 3 type II collagen 
expression. At Day 10, (TGF-β3→DCM) remains relatively unchanged in type II
collagen expression at a mean fold change of (-0.40±1.31). At Day 3 and Day 10, Group 
(TGF-β3→BMP-13) and Group (TGF-β3→DCM) do not exhibit a significant difference
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in type II collagen expression. Total type II collagen mean fold change for the groups at 
each time point for the first follow-up experiment is displayed in Figure 3.14.
Figure 3.14 Total type II collagen mean fold change in pellets over time for first follow-
up experiment.
Group (TGF-β3→BMP-13) exhibits a mean (377.85±76.63) fold change at Day 3 
type X collagen expression. At Day 10, (TGF-β3→BMP-13) undergoes a significant 
decrease in type X collagen expression at a mean fold change of (4.21±0.52). Group 
(TGF-β3→DCM) exhibits a mean (441.715±19.58) fold change at Day 3 type X collagen 
expression. At Day 10, (TGF-β3→DCM) undergoes a significant decrease in type X
collagen expression at a mean fold change of (3.74±0.38). At Day 3 and Day 10, Group 
(TGF-β3→BMP-13) and Group (TGF-β3→DCM) do not exhibit a significant difference
47
  








   
   
 
in type X collagen expression. Total type X collagen mean fold change for the groups at 
each time point for the first follow-up experiment is displayed in Figure 3.15.
Figure 3.15 Total type X collagen mean fold change in pellets over time for first follow-
up experiment.
The second follow-up experiment was designed to investigate the potential for
BMP-13 to mitigate the TGF-β3-induced upregulation of type X collagen expression.
The experimental groups were TGF-β3 and a new group, (TGF-β3→Combination), in 
which 10 ng/ml BMP-13 was added to the TGF-β3 containing medium after Day 3. Total 
RNA was prepared from undifferentiated MSCs and also from pellets cultured at day 10 
using the Qiagen RNeasy mini kit. RT-PCR analysis followed the same experimental 










     
 
Group TGF-β3 exhibits a mean (18.76±3.38) fold change at Day 10 type X 
collagen expression. Group (TGF-β3→Combination) exhibits a mean (21.66±0.00) fold 
change at Day 10 type X collagen expression. By Day 10, Group TGF-β3 and Group 
(TGF-β3→Combination) do not exhibit a significant difference in type X collagen 
expression. Total type X collagen mean fold change for the groups at each time point for
the second follow-up experiment is displayed in Figure 3.16.










   
   
  
 
   
    
  
   
   
  
  







In this study, the concentration and time interval of growth factors, TGF- β3 and 
BMP-13, are manipulated in order to determine their effect on chondrogenic
differentiation of bone marrow-derived MSCs. The hypothesis, that human bone marrow-
derived MSCs can be driven to differentiate toward a chondrogenic lineage after the
application of BMP-13, was tested by the analyses presented. The results indicate that the
application of BMP-13 alone does not exert a strong chondroinductive effect on MSCs. 
However, the data does suggest that BMP-13 has the ability to sustain chondroinduction
to a certain extent for up to 18 days following initiation by 3 days of exposure to TGF-β3.
The total GAG content was found to be significantly higher for Group I compared 
to that of Group II and Group IV at the first experimental time point. Group III was not
considered significantly different from any of the other treatment groups at Day 3. 
Following the initial time point, GAG content for all treatment groups was significantly
higher than on Day 3 by 135%, and all groups did not significantly differ with regards to 
GAG content. The significant increase in GAG content suggests that all Groups promote 
differentiation of MSCs from Day 3 to Day 10. From Day 10 to Day 21, GAG content 
was not significantly different for all treatment groups between time points, and treatment 
groups again exhibited no significant difference in GAG content when compared to one 
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another. Previous studies have reported an initial increase, and the leveling off of GAG 
content in cartilage tissue engineering [49]. This leveling of GAG content could be 
associated with a higher turnover per cell accompanying the decrease in DNA content
presented across groups [30]. Previous studies, comparing seeding cell density, have
reported that a higher initial cell-density has been proven to produce more proteoglycan
in the presence of TGF- β3 [50, 51].
The total DNA content was found to be similar among the treatment groups at the
first experimental time point. Following the initial time point, there is a significant 
decrease in DNA content in all treatment groups, suggesting cellular death. Group I and 
Group III had significantly higher DNA content at Day 10 and Day 21 compared to that 
of Group II and Group IV. Group I also had a significantly higher DNA content than 
Group III at Day 21. All treatment groups containing growth factors, Group II, Group III,
and Group IV, had a significantly lower DNA content compared to pellets cultured in 
expansion medium, Group I. Groups do not demonstrate a significant change in DNA
content from Day 10 to Day 21, indicating the maintenance of cell density. The results 
suggest that MSCs were lost at the initiation of chondroinduction. The sections stained 
with H&E also indicate the loss of cells, which is indicated by the collection of cellular
debris in the center of all pellets over time. The loss of MSCs in pellet culture with 
additional growth factors has been reported by previous studies [52, 53]. These studies 
also reported loss of DNA content in pellets induced by TGF-β and BMP growth factors, 
suggesting little cell proliferation or apoptosis throughout the course of differentiation.
Aggrecan fold change was found to be significantly higher for Group II, Group 





   
   
  
 
     













   
 
Aggrecan expression for all treatment groups express a negative fold change value, 
indicating little presence or absence of the aggrecan protein at Day 3. Following the 
initial time point, Group II expresses a significantly higher mean fold change compared 
to that of Group III at Day 10. After the removal of growth factor TGF-β3 and the 
addition of growth factor BMP-13, Group IV experiences a significant decrease in mean 
fold change in aggrecan gene expression from Day 3 to Day 10. At Day 10, all treatment 
groups again express a negative aggrecan mean fold change. Treatment groups at Day 21 
all exhibit a significant difference from one another. Group II expresses a significantly
higher mean fold change and Group I a significantly lower mean fold change. Group II
and Group III both exhibit positive mean fold change aggrecan expression by Day 21. 
Aggrecan message was not detected in the MSCs of Group I by RT-PCR, but appeared 
after treatment with TGF-β3 and BMP-13 after 21 days. The results suggest that growth 
factor BMP-13, similar to that of TGF-β3, originally do not encourage the expression of
aggrecan, but slowly seem to support the presence of aggrecan with a positive mean fold 
change by Day 21. The initial absence of aggrecan expression for groups may be an 
effect of pelleting at the initiation of the experiment. Previous studies have also reported
that growth factor BMP-13 induced upregulation of the mature chondrocyte marker, 
aggrecan [37].
COMP mean fold change was found to be significantly higher for Group II and 
Group IV compared to that of the remaining groups at the initial experimental time point. 
Following Day 3, Group II continues to express a significantly higher mean fold change
compared to the remaining treatment groups at both Day 10 and Day 21. Group II is the






      
  
    
   
   
 
 
    
     
  
   
 
   
     
      
  
    
    
    
throughout the experiment. Group IV initiates the production of COMP at Day 3, but 
following the removal of TGF-β3 and addition of BMP-13 COMP mean fold change
significantly decreases. COMP message was not detected in the MSCs of Group I by RT-
PCR and appeared after treatment with TGF-β3. The results and previous studies indicate 
the ability of TGF- β3 to initiate COMP expression, and the limited ability BMP-13 to 
initiate or sustain the expression of the protein [30].
Type I collagen expression for Group II and Group IV exhibit a significantly
higher mean fold change compared to the remaining groups at the initial experimental 
time point. Following Day 3, Group II continues to exhibit the highest significant mean 
fold change among treatment groups at Day 10 and Day 21. Group II, Group III, and 
Group IV have significantly higher mean fold change type I collagen expression 
compared to that of the MSCs of Group I at Day 21. Following the removal of TGF-β3 
and the addition of BMP-13 to DCM in Group IV at Day 3, type I collagen expression 
remains relatively unchanged. The results suggest that BMP-13 may be capable of
sustaining the type I collagen expression initiated by TGF-β3. Type I collagen is detected 
under the influence of both growth factors. 
In terms of chondrogenic differentiation, type I collagen is not desirable. Growth 
factor BMP-13 demonstrates a significantly lower expression of type I collagen,
compared to that of the growth factor TGF- β3. Barry et al. also report the type I collagen 
uniform expression throughout differentiation in the presence of TGF- β3. Collagen type
I gene was expressed in the TGF- β3 and BMP-13 treated pellets. These results suggest
that the MSCs may not have completely differentiated into chondrocyte-like cells after a 




   
 
      
    
   
 
  
   
   
     
   
    
        
  
  
   
 
    
  
Nochi et al. also reported no suppression of type I collagen by the growth factor BMP-13, 
although the osteogenic phenotype associated with type I collagen had been diminished 
through the use of another member of the bone morphogenic protein family, BMP-2.
Type I collagen message showed a gradual increase in the untreated MSCs of
Group I, and was readily detected after 21 days in pellet culture. The presence of type I
collagen in the control group, Group I, at Day 21 suggests the osteogenic potential of
human bone marrow-derived MSCs, which has been suggested in previous studies in 
regards to the C3H10T1/2 cell line [37]. 
Type II collagen expression is significantly higher for Group II and Group IV
compared to that of Group III at the initial experimental time point. Following Day 3, all 
treatment groups express no significant difference in mean fold change for type II
collagen expression. However, Group IV undergoes a significant decrease in mean fold 
change in type II collagen expression, following the removal of growth factor TGF-β3
and addition of growth factor BMP-13 to the DCM. At Day 21, Group II shows a
significantly higher type II collagen expression compared to that of the remaining
treatment group, suggesting that TGF- β3 may have the ability to increase type II
collagen expression more than that of BMP-13. Type II collagen expression remains 
relatively unchanged for Group I, Group II and Group III over the course of the 
experiment. Type II collagen message was uniformly detected in the MSCs of Group I
and throughout differentiation in pellet culture. Previous studies indicate a gradual 
increase over time in type II collagen under the influence of TGF- β3 [30], and an 





   
   
  








    
    
     
   
 
 
    
   
 
could be a reflection of the differentiation state of cells under study, rather than the
signals being transduced by the BMP-13 growth factor.
Type X collagen expression is significantly higher for Group II and Group IV
compared to that of Group I and Group III at the initial experimental time point. At Day
10, Type X collagen expression for Group II expresses a significantly higher mean fold 
change compared to the remaining treatment groups. Group IV experiences a significant 
decrease in type X collagen expression from Day 3 to Day 10. Group II type X collagen 
expression experiences a significantly higher mean fold change compared to that of the
remaining treatment groups at Day 21. As expected, Group II, under the influence of 
TGF-β3, experiences a significantly higher mean fold change compared to that of all
treatment groups, and undergoes significant increases in type X collagen over time. 
Previous reports also have stated that in the presence of TGF-β3, MSCs display an up-
regulation of type X collagen over time [30, 55]. However, Group IV undergoes a 
significant decrease in type X collagen expression following the removal of growth factor
TGF- β3 and addition of growth factor BMP-13 to DCM. The results suggest that BMP-
13 does not promote the expression of type X collagen.
Following initial experiments, the question still remained whether BMP-13 was 
responsible for suppressing the expression of certain genes, or if it was the removal of
TGF-β3 that lead to the decrease in gene expression. Group IV undergoes a significant 
decrease in gene expression for aggrecan, COMP, type II collagen, and type X collagen
at Day 10, following the removal of TGF-β3 and the addition of BMP-13. Follow-up 





       











      




    
  
   
The first follow-up experiment was designed to determine whether BMP-13 was 
responsible for any elevation in chondrocyte gene markers after 3 days of
chondroinduction by TGF-β3. The results suggest the limited ability of BMP-13 to 
induce chondroinduction of MSCs. The aggrecan expression for Group (TGF-β3→BMP-
13) and Group (TGF-β3→DCM) undergoes a significant decrease following the removal 
of TGF- β3 at Day 3. Group (TGF-β3→BMP-13) and Group (TGF-β3→DCM) exhibit 
no significant difference in aggrecan expression from one another at Day 10. The results 
suggest that the removal of TGF-β3 is responsible for a significant decrease in mean fold 
change of aggrecan expression. BMP-13 is not responsible for the suppression of the
aggrecan gene, but may experience an initial decrease in mean fold change like that seen 
in the initial experiment, to be followed by a significant increase in aggrecan mean fold 
change.
The COMP expression for Group (TGF-β3→BMP-13) and Group (TGF-
β3→DCM) undergoes a significant decrease following the removal of TGF- β3 at Day 3. 
Group (TGF-β3→BMP-13) and Group (TGF-β3→DCM) exhibit no significant 
difference in COMP expression from one another at Day 10. The results suggest that the
removal of TGF-β3 is responsible for a significant decrease in COMP expression. BMP-
13 is not responsible for the suppression of the COMP gene.
Type II collagen expression for Group (TGF-β3→BMP-13) and Group (TGF-
β3→DCM) remains relatively unchanged following the removal of TGF- β3 at Day 3. 
Group (TGF-β3→BMP-13) and Group (TGF-β3→DCM) exhibit no significant 
difference in type II collagen expression from one another at Day 10. The results suggest 
that the initial presence of TGF- β3 is responsible for the expression of type II collagen.
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BMP-13 does not seem to play a vital role in the up-regulation or sustainability in the
expression of type II collagen.
Type X collagen expression for Group (TGF-β3→BMP-13) and Group (TGF-
β3→DCM) undergoes a significant decrease following the removal of TGF- β3 at Day 3. 
Group (TGF-β3→BMP-13) and Group (TGF-β3→DCM) exhibit no significant 
difference in type X collagen expression from one another at Day 10. The results suggest 
that the removal of TGF-β3 is responsible for a significant decrease in type X collagen 
expression. BMP-13 is not responsible for the suppression of the type X collagen gene.
The second follow-up experiment was designed to better understand the affect of 
BMP-13 on the alleviation of type X collagen in TGF- β3 induced MSCs. The results 
suggest the limited ability of BMP-13 to repress type X collagen following initiation with 
TGF-β3. Type X collagen expression for Group (TGF-β3) and Group (TGF-
β3→Combination) exhibit no significant difference relative to type X collagen expression
at Day 10. From the initial experiment, we recognize that TGF-β3 is responsible for a
significant increase in type X collagen expression. BMP-13, when added in combination 
with TGF-β3, exhibits no capabilities of suppressing type X collagen expression.
In summary, this study has demonstrated that chondrogenesis of human bone
marrow-derived MSCs can be sustained with the treatment of BMP-13 as attested by the 
results of gene expression analyses and histological and immunohistochemical 
assessments. BMP-13 appears to have some limited capacity for chondroinduction, much 
less than that of pellet cultures stimulated by TGF-β3. However, the chondroinduction 
stimulated by BMP-13 is not accompanied by an increase in type I collagen and type X 




   
 
  
     





In this study, we proved that BMP-13 is capable of stimulating proliferation and 
the aggregation of undifferentiated MSCs. BMP-13 is able to sustain type II collagen 
expression following initiation with TGF-β3, but alone does not have the capability to 
express the protein considered to be the basis of articular cartilage. BMP-13 does not 
exert a strong influence on the expression of chondrogenic specific markers, aggrecan, 
COMP, and type II collagen, but BMP-13 does not act to suppress the expression of these
genetic markers. Initial experiments prematurely suggested that BMP-13 might be 
responsible for the suppression the expression of aggrecan, COMP, type II collagen and 
type X collagen. However, follow-up experiments reported that the removal of TGF-β3 
was responsible for the significant decrease in gene expression. In order to improve this 
method of tissue engineering, future studies should be conducted to establish the model
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